Sign inJoin free

Watch / Small Cap

Small caps stocks with upside

20 Mar 20264:11

Small caps stocks with upside

General information only. ausbiz videos are general information only, produced by Ausbiz TV Pty Ltd, a media business that doesn’t give financial advice. They don’t take into account your objectives, financial situation or needs. Consider whether it’s right for you and read the PDS and TMD before acting on anything you watch.

About this video

Key Points:

  • Selective, well-backed small caps still seen as attractive in a higher-rate environment

  • Vinyl Group (ASX:VNL) viewed as undervalued, with a transformative Val Morgan Digital deal pending

  • EVE Health Group (ASX:EVE) seen as a turnaround story via its Limbo erectile dysfunction product

  • Comparison drawn with LTR Pharma (ASX:LTP), with convenience of delivery highlighted as a differentiator

John Athanasiou from Red Leaf Securities outlines a cautiously optimistic view on small caps, despite what he describes as a “double whammy” of a software sell-off, geopolitical tensions and rising global interest rates. Athanasiou argues that higher rates typically pressure small caps, yet maintains that selective investors in well-backed names can still, in his view, achieve strong returns.

Athanasiou highlights Vinyl Group (ASX:VNL), formerly Jaxsta, as a key pick. He values the music media and technology company at 19 cents per share on a base case and points to what he calls a “transformative” pending acquisition of Val Morgan Digital. He states this deal could give Vinyl Group around 40% of Australia’s digital market, with scope to buy undervalued cultural assets at attractive prices. He considers the presence of major backers, including Richard White, as a significant support for the growth-by-acquisition strategy.

EVE Health Group (ASX:EVE) is another favoured small cap, despite its weak share price performance. Athanasiou focuses on its shift from Manuka honey towards medical products, highlighting a new erectile dysfunction treatment, Limbo. He notes funds were recently raised to pursue TGA approval and compares EVE with LTR Pharma (ASX:LTP), suggesting EVE’s oral strip delivery may be more convenient than LTR’s nasal product and could underpin a re-rating.

More like this

We value your privacy

We use essential cookies to make the site work. Non-essential cookies help us improve the experience. You can accept or reject non-essential cookies. Privacy policy